

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)
 Government of India
 Ministry of Chemicals and Fertilizers
 Department of Pharmaceuticals
 National Pharmaceutical Pricing Authority

New Delhi, 19th December, 2022

ORDER

S.O. 5937(E):-In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Amoxicillin and Potassium Clavulanate Oral Suspension IP	Each Combi pack contains: (A) Amoxicillin and Potassium Clavulanate Oral Suspension IP Composition: Each 5ml of Reconstituted suspension contains: Amoxicillin Trihydrate IP eq. to Amoxicillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg (B) 2 Ampoule of 25ml each of Sterile Water for Reconstitution of Dry Syrup	Combi Pack	M/s Malik Lifesciences Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd.	168.43
2.	Metformin Hydrochloride (SR), Glimepiride and Voglibose Tablets	Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 1000mg (as Sustained Release form) Glimepiride IP 1mg Voglibose IP 0.2mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd.	11.60
3.	Metformin Hydrochloride (SR), Glimepiride and Voglibose Tablets	Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 1000mg (as Sustained Release form) Glimepiride IP 2mg Voglibose IP 0.2mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd.	13.18
4.	Ceftazidime and Avibactam powder for	Each vial contains: Ceftazidime (pentahydrate) IP eq. to Ceftazidime 2mg	Per Vial	M/s Cipla Limited	2500.00

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	concentrate for solution for infusion	Avibactam Sodium eq. to Avibactam 0.5gm Sodium content approx. 148mg (6.4meq)/vial			
5.	Moxifloxacin Hydrochloride and Loteprednol Ophthalmic Suspension	Composition: Moxifloxacin Hydrochloride IP eq. to Moxifloxacin 0.5% w/v Loteprednol Etabonate 0.5% w/v (Sterile & Micronized) Sterile aqueous buffered vehicle q.s.	Per ml	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Limited	27.43
6.	Itraconazole Capsules 65mg (Supra-Bioavailable Formulation)	Each hard gelatin capsule contains: Itraconazole BP 65mg	1 Capsule	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Mankind Pharma Ltd.	11.60
7.	Acetylcysteine & Acebrophylline Tablets	Each film coated tablet contains: Acetylcysteine BP 600mg Acebrophylline 100mg	1 Tablet	M/s Pure and Care Healthcare Pvt. Ltd. / M/s Cadila Pharmaceuticals Limited	14.91
8.	Paracetamol, Phenylephrine Hydrochloride, Caffeine & Diphenhydramine Hydrochloride Tablets	Each uncoated tablet contains: Paracetamol IP 500mg Phenylephrine HCl IP 5mg Caffeine IP 30mg Diphenhydramine HCl IP 25mg	1 Tablet	M/s Dallas Drugs Pvt. Ltd. / M/s Micro Labs Pvt. Ltd.	2.76
9.	Rabeprazole and Ondansetron tablets	Each Enteric coated tablet contains: Rabeprazole Sodium IP 20mg Ondansetron Hydrochloride IP eq. to Ondansetron 4mg	1 Tablet	M/s Dallas Drugs Pvt. Ltd. / M/s Micro Labs Pvt. Ltd.	5.90
10.	Amoxicillin and Potassium Clavulanate Oral Suspension IP	Each 5ml of Reconstituted suspension contains: Amoxicillin Trihydrate IP eq. to Amoxicillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg	Per Vial (50ml)	M/s Malik Lifesciences Pvt. Ltd. / M/s Zuventus Healthcare Limited	168.43

Note:

- The manufacturer of above-mentioned formulations i.e., "new drug" under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall

issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

PN/237/105/2022/F

F. No. 8(105)/2022/D.P./NPPA-Div.-II

(Mahaveer Saini)
Deputy Director